Intarcia Appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations, Reporting To Chairman & CEO Kurt Graves

- Role vital to Intarcia's global build-out in commercial manufacturing; recognizes the near-term opportunity created by ITCA 650, but also multiple new pipeline projects -

News provided by

Intarcia Therapeutics, Inc.

Apr 05, 2016, 09:00 ET

BOSTON, April 5, 2016 /PRNewswire/ -- Intarcia Therapeutics, Inc., today announced Anthony Hurley has joined the Company in the role of VP, Global Commercial Manufacturing and Operations, based in Hayward, CA. Tony is an executive officer of the Company and serves as a member of the Leadership Team, reporting directly to Chairman, President and CEO, Kurt Graves. Most recently Tony served as Genentech's VP, Head of Global External Manufacturing – Biologics. He spent the last eleven years of his career at Genentech in positions of increasing responsibility including Head of South San Francisco Manufacturing Operations and Head of Global Quality Biologics for both Drug Substance and Drug Product. His immediate responsibilities at Intarcia will be to provide the manufacturing support for the potential global launch of Intarcia's novel drug-device platform to treat type 2 diabetes. Specifically, Mr. Hurley will lead and continue to build out the commercial manufacturing team necessary to accomplish the commercial production/scale-up and facility expansions in the US and abroad. The new position is part of Intarcia's rapid expansion to bring new capabilities in-house to further advance the Company's disruptive innovations to market so that one of the world's most prevalent, costly and devastating chronic diseases − type 2 diabetes – might be more effectively addressed.

Intarcia appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations. Hurley comes from Genentech where he was a high-ranking executive.

"Tony is a world-class and consummate professional in his areas of expertise, so we're delighted to be gaining his demonstrated leadership capabilities, his passion for quality and top-tier performance, and his entrepreneurial fit with our culture," said Kurt Graves. "The leadership, talent, and operational tasks that Tony will take-on and lead are some of our most critical, and their success is essential to bringing our innovative progress to the millions of patients we believe we can help achieve better outcomes in type 2 diabetes. This means everything to us, and I know Tony shares our deep commitment to quality, delivery, and winning on behalf of patients. I have full confidence in our team, and the opportunity to bring in Tony will surely expand the magnitude of our success with our mission."

"Intarcia is well into the process of creating a transformational opportunity for medical providers to improve how medicine is delivered in chronic diseases for many patients," said Anthony Hurley. "The opportunity to further develop and build the manufacturing organization and supply chain is so great, it could be a once in a career chance to make such a great difference. Having met Kurt and his team, I became convinced the Company was on the right course to accomplish its mission. And the culture Kurt has firmly established − that business success will follow winning on behalf of patients − is something I believe deeply. I want that prioritization and sense of urgency when I come to work everyday, so I'm excited to invest myself fully in what needs to be done. I hope to look back at these next years as a time and a team that did some incredible work with some incredible innovation, results and progress for patients."

Mr. Hurley was selected because he is a great fit in terms of his proven leadership, his commercial manufacturing and quality expertise, Intarcia's expanding operational needs and the Company's work culture. He will serve as an executive leader in the company broadly, shouldering a large and mission-critical responsibility for the scale-up of ITCA 650 for our planned global launch. Tony and the rest of the team in Hayward will also finalize plans and important work on our second manufacturing facility in Ireland, and eventually progressing our novel pipeline programs when they reach the right stage of development.

Prior to his decade-long career in senior positions at Genentech, Inc., Mr. Hurley spent seventeen years in positions of increasing responsibility at GlaxoSmithKline (GSK) from 1987 to 2004, beginning as a Primary Plant Process Engineer and advancing through the ranks to his most senior role as Site Director, Upper Merion Anti-Infectives Operations, where he oversaw 280 employees. Before this, Tony spent two years as at Schering Plough as a Pilot Plant Engineer/Supervisor.

Mr. Hurley received his B.Sc. degree in Chemical Engineering at the Cork Institute of Technology, Cork, Ireland, and his M.Sc. Degree in Industrial Engineering from Rutgers University, NJ.

About ITCA 650
ITCA 650 (continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform, a matchstick-size, miniature osmotic pump that is placed sub-dermally to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic peptides above human body temperature for extended periods of time. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist that is currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. When approved, ITCA 650 will be the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement of the osmotic mini-pump. ITCA 650 is currently being evaluated in the FREEDOM global Phase 3 clinical trial program. The first three FREEDOM trials have successfully completed, the latest, FREEDOM 2, demonstrated head-to-head superiority in glucose control after 52 weeks over the market-leading oral therapy, Januvia^® (sitagliptin). The FREEDOM CVO trial began close out procedures in 4Q15 after reaching the target number of major cardiovascular events. Intarcia expects to have top-line results for FREEDOM CVO in 2Q 2016.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly has the potential to ensure improved patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is conducting a Phase 3-stage development program for type 2 diabetes that consists of four separate clinical trials, three of which have been completed. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes and obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.

Photo - http://photos.prnewswire.com/prnh/20160405/351510

Logo - http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO

SOURCE Intarcia Therapeutics, Inc.